These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 31997633)
1. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633 [TBL] [Abstract][Full Text] [Related]
2. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794 [TBL] [Abstract][Full Text] [Related]
3. ZnAs@SiO Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768 [No Abstract] [Full Text] [Related]
4. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy. Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416 [TBL] [Abstract][Full Text] [Related]
5. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899 [TBL] [Abstract][Full Text] [Related]
6. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells. Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461 [TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078 [TBL] [Abstract][Full Text] [Related]
8. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843 [TBL] [Abstract][Full Text] [Related]
9. Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma. Jin Z; Yi X; Yang J; Zhou M; Wu P; Yan G Int J Nanomedicine; 2021; 16():3775-3788. PubMed ID: 34113100 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Zhang X; Hu B; Sun YF; Huang XW; Cheng JW; Huang A; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J; Yang XR Clin Transl Med; 2021 Feb; 11(2):e335. PubMed ID: 33634982 [TBL] [Abstract][Full Text] [Related]
11. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700 [TBL] [Abstract][Full Text] [Related]
12. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma. Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495 [TBL] [Abstract][Full Text] [Related]
13. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302 [TBL] [Abstract][Full Text] [Related]
14. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599 [TBL] [Abstract][Full Text] [Related]
15. Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation? Fu X; Li YS; Zhao J; Yu LL; Luo RG; Liang QR; Tang Q Mini Rev Med Chem; 2020; 20(3):239-251. PubMed ID: 31760930 [TBL] [Abstract][Full Text] [Related]
16. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690 [TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide-loaded CalliSpheres: Duan X; Zhao G; Han X; Ren J; Li H; Chen P; Wang M; Ju S Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 33982781 [TBL] [Abstract][Full Text] [Related]
18. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced. Song X; Wang J; Xu Y; Shao H; Gu J Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma. Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]